Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy.
International journal of radiation oncology, biology, physics
oregon; portland; ppmc; chiles
PURPOSE: The role of MerTK, a member of the Tyro3-Axl-MerTK family of receptor tyrosine kinase, in the immune response to radiation therapy (RT) is unclear. We investigated immune-mediated tumor control after RT in murine models of colorectal and pancreatic adenocarcinoma using MerTK wild-type and knock-out hosts and whether inhibition of MerTK signaling with warfarin could replicate MerTK knock-out phenotypes.
METHODS AND MATERIALS: Wild-type and MerTK
CONCLUSIONS: MerTK inhibits adaptive immune responses after SABR. Because warfarin inhibits MerTK signaling and phenocopies genetic deletion of MerTK in mice, warfarin therapy may have beneficial effects in combination with SABR and immune therapy in patients with cancer.
Tormoen, Garth W; Blair, Tiffany C; Bambina, Shelly; Kramer, Gwen; Baird, Jason; Rahmani, Ramtin; Holland, John M; McCarty, Owen J T; Baine, Michael J; Verma, Vivek; Nabavizadeh, Nima; Gough, Michael J; and Crittenden, Marka, "Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy." (2020). Articles, Abstracts, and Reports. 4931.